The global cancer immunotherapy market is valued at USD 145 billion in 2025, and Contrive Datum Insights projects it will reach USD 163.5 billion in 2026 and USD 483.04 billion by 2034, a compound annual growth rate of 14.5% across the forecast period.
Cancer immunotherapy covers biologic treatments that direct or restore the immune system's capacity to identify and destroy tumor cells, distinct from chemotherapy or radiation, which act on the tumor directly. The report groups these therapies into four product lines: monoclonal antibodies (including checkpoint inhibitors), immunomodulators, oncolytic viral therapies, and cancer vaccines, most administered by infusion or injection in a clinical setting. Purchasers include hospital and specialty oncology pharmacies, cancer research and treatment centers, and the health systems and payers that reimburse a course of treatment.
Expanding checkpoint inhibitor label indications is the largest single contributor to growth over the forecast period, rated a high-impact driver in the study. The product lines most exposed to it move faster than the market average: oncolytic viral therapies compounds at 20.21% a year, lifting its share of revenue from 5.8% in 2025 to 9% by 2034 and its value from USD 8.41 billion to USD 43.47 billion.
Monoclonal antibodies remain the largest product line, holding 67.7% of 2025 revenue at USD 98.17 billion and 60% of the market by 2034. Its own growth rate, 12.96% a year, trails the market's 14.5%. Lung cancer leads by application, with 28% of 2025 revenue (USD 40.6 billion), while pancreatic cancer grows fastest among applications at 19.58%. Hospital pharmacies account for 78% of 2025 distribution revenue (USD 113.1 billion); online pharmacy is the fastest-growing channel at 20.19%. Hospitals and clinics take 82% of 2025 end-use revenue (USD 118.9 billion), and cancer research centers expand fastest there, at 16.29%. By therapy, monotherapy holds 58% of 2025 revenue (USD 84.1 billion), and combination therapy grows fastest at 17.04%.
North America is the largest region, holding 44.1% of 2025 revenue (USD 63.95 billion) and reaching USD 188.39 billion by 2034. Asia Pacific's share climbs from 22.7% in 2025 to 28.5% in 2034 as its revenue grows from USD 32.92 billion to USD 137.67 billion, the fastest regional gain in the study. Middle East and Africa stays the smallest region throughout, moving only from 4.4% to 5% of global revenue. Within North America, the United States alone accounts for USD 54.36 billion in 2025, 37.49% of the global total.
The USD 483.04 billion base case for 2034 assumes combination-regimen trials continue to read out on schedule and reimbursement conditions hold roughly where they stand today. A missed endpoint in a major combination trial, or tighter reimbursement for high-cost immunotherapy in a large payer market, would slow the shift away from monotherapy and pull biosimilar-driven price erosion forward, holding 2034 revenue closer to USD 434.74 billion. The reverse scenario, combination-regimen adoption and biosimilar-free monoclonal-antibody pricing holding longer than currently modeled, would instead produce the study's higher case of USD 541 billion.